Zoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 21, 2025
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction | (Commission File | (I.R.S. Employer | ||||||||||||
| of incorporation) | Number) | Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(973 ) 822-7000
| (Registrant's telephone number, including area code) | ||
| Not Applicable | ||
| (Former Name or Former Address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.
Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting. On May 22, 2025, the Company issued a press release announcing the election of Dr. Stetter. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
As discussed under Item 5.02 of this Current Report on Form 8-K, on May 21, 2025, the Company held the Annual Meeting. At the Annual Meeting, the Company’s shareholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 9, 2025 (the “Proxy Statement”). There were 392,890,991 shares of common stock present at the Annual Meeting in person or by proxy, which represented 88.08% of the voting power of the shares of common stock entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. Holders of the Company’s common stock were entitled to one vote for each share held as of the close of business on March 28, 2025 (the “Record Date”).
The shareholders of the Company voted on the following proposals at the Annual Meeting:
1. To elect twelve directors, each to serve for a one-year term until the 2026 Annual Meeting of Shareholders or until each director’s successor has been elected and qualified, or until such director’s earlier death, resignation or removal.
2. A non-binding advisory vote on the compensation program for the Company’s named executive officers as disclosed in the Proxy Statement.
3. To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
4. To approve a shareholder proposal regarding a special shareholder meeting improvement.
The voting results for each of these proposals are detailed below.
1. Election of Directors
| Nominee | Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||||
| Paul M. Bisaro | 369,537,255 | 2,013,136 | 524,266 | 20,816,334 | ||||||||||
| Vanessa Broadhurst | 367,646,157 | 3,694,456 | 734,044 | 20,816,334 | ||||||||||
Frank A. D'Amelio | 350,971,578 | 20,566,366 | 536,713 | 20,816,334 | ||||||||||
| Gavin D.K. Hattersley | 367,143,208 | 4,384,681 | 546,768 | 20,816,334 | ||||||||||
| Sanjay Khosla | 363,294,340 | 8,250,547 | 529,770 | 20,816,334 | ||||||||||
| Antoinette R. Leatherberry | 370,300,160 | 1,239,724 | 534,773 | 20,816,334 | ||||||||||
Michael B. McCallister | 355,271,093 | 16,276,093 | 527,471 | 20,816,334 | ||||||||||
| Gregory Norden | 346,322,416 | 24,910,002 | 842,239 | 20,816,334 | ||||||||||
| Louise M. Parent | 359,379,090 | 12,177,746 | 517,821 | 20,816,334 | ||||||||||
| Kristin C. Peck | 366,830,103 | 3,876,770 | 1,367,784 | 20,816,334 | ||||||||||
| Willie M. Reed | 363,493,695 | 7,857,615 | 723,347 | 20,816,334 | ||||||||||
| Mark Stetter | 371,157,755 | 379,799 | 537,103 | 20,816,334 | ||||||||||
Each of the twelve nominees for director was elected to serve for a one-year term until the 2026 Annual Meeting of Shareholders or until each director’s successor has been elected and qualified, or until such director’s earlier death, resignation or removal.
2. Advisory Vote on Executive Compensation
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 334,181,202 | 35,190,564 | 2,702,891 | 20,816,334 | ||||||||
The shareholders approved, on a non-binding advisory basis, the compensation program for the Company’s named executive officers as disclosed in the Proxy Statement.
3. Ratification of Appointment of Independent Registered Public Accounting Firm
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 384,785,460 | 7,615,268 | 490,263 | — | ||||||||
The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
4. Shareholder Proposal
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 50,420,440 | 320,662,986 | 991,231 | 20,816,334 | ||||||||
The shareholders did not approve the shareholder proposal regarding a special shareholder meeting improvement.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Description | |||||
| Press Release issued on May 22, 2025, regarding the election of Dr. Mark Stetter. | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZOETIS INC. | ||||||||
| Dated: May 22, 2025 | By: | /s/ Roxanne Lagano | ||||||
| Roxanne Lagano | ||||||||
| Executive Vice President, | ||||||||
| General Counsel and Corporate Secretary | ||||||||